I'm Francis deSouza, the CEO of Illumina. As a reminder, our presentation today includes forward-looking statements, non-GAAP measures and reconciliations to GAAP measures. Please refer to our SEC filings for a presentation of risks. Also, please review our statements on the whole separate requirement related to GRAIL. GRAIL must be held and operated separately and independently from Illumina pursuant to the interim measures ordered by the European Commission, which prohibited our acquisition of GRAIL. Today, I'll cover three areas in our presentation. First, a company overview, including preliminary 2022 results and 2023 guidance; second, I'll review our sequencing platforms business and NovaSeq X; and third, I'll cover how we're accelerating clinical genomics, including an update on GRAIL. I'll start with who we are. Our mission at Illumina is to improve human health by unlocking the power of the genome.